A GMCSF and IL7 fusion cytokine leads to functional thymic-dependent T-cell regeneration in age-associated immune deficiency.

Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol (2002) 15.33

Seven-transmembrane receptors. Nat Rev Mol Cell Biol (2002) 11.50

Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J Exp Med (1994) 8.97

Age-related changes in lymphocyte development and function. Nat Immunol (2004) 6.16

Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood (2009) 4.80

Thymopoiesis independent of common lymphoid progenitors. Nat Immunol (2003) 4.52

The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance. J Immunol (2005) 3.51

Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med (2008) 3.48

Age-associated decline in T cell repertoire diversity leads to holes in the repertoire and impaired immunity to influenza virus. J Exp Med (2008) 3.15

Interleukin-7: from bench to clinic. Blood (2002) 3.01

Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest (2009) 2.92

Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer (2012) 2.79

Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity (2011) 2.64

Ageing and life-long maintenance of T-cell subsets in the face of latent persistent infections. Nat Rev Immunol (2008) 2.58

IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood (2009) 2.50

The ageing immune system: is it ever too old to become young again? Nat Rev Immunol (2009) 2.48

Growth hormone enhances thymic function in HIV-1-infected adults. J Clin Invest (2008) 2.35

T cell development and receptor diversity during aging. Curr Opin Immunol (2005) 2.29

Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol (2011) 2.25

Thymic-independent T cell regeneration occurs via antigen-driven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing. J Immunol (1996) 2.24

Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood (1999) 2.22

Fate mapping reveals separate origins of T cells and myeloid lineages in the thymus. Immunity (2010) 2.11

IL-22, not simply a Th17 cytokine. Immunol Rev (2013) 2.04

Human TH17 cells are long-lived effector memory cells. Sci Transl Med (2011) 1.99

Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis. Blood (2010) 1.88

Murine thymocytes proliferate in direct response to interleukin-7. Blood (1989) 1.86

Differential effects of STAT5 and PI3K/AKT signaling on effector and memory CD8 T-cell survival. Proc Natl Acad Sci U S A (2010) 1.85

Ghrelin promotes thymopoiesis during aging. J Clin Invest (2007) 1.83

Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation. Blood (2012) 1.81

Keratinocyte growth factor and androgen blockade work in concert to protect against conditioning regimen-induced thymic epithelial damage and enhance T-cell reconstitution after murine bone marrow transplantation. Blood (2008) 1.77

Sustained thymopoiesis and improvement in functional immunity induced by exogenous KGF administration in murine models of aging. Blood (2006) 1.71

IL-7 enhances peripheral T cell reconstitution after allogeneic hematopoietic stem cell transplantation. J Clin Invest (2003) 1.56

Thymic T-cell development in allogeneic stem cell transplantation. Blood (2011) 1.53

Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease. Blood (2001) 1.52

The murine cytomegalovirus immunomodulatory gene m152 prevents recognition of infected cells by M45-specific CTL but does not alter the immunodominance of the M45-specific CD8 T cell response in vivo. J Immunol (2002) 1.52

Exogenous IL-7 increases recent thymic emigrants in peripheral lymphoid tissue without enhanced thymic function. Blood (2004) 1.42

Thymic function in young/old chimeras: substantial thymic T cell regenerative capacity despite irreversible age-associated thymic involution. Eur J Immunol (1998) 1.35

A granulocyte-macrophage colony-stimulating factor and interleukin-15 fusokine induces a regulatory B cell population with immune suppressive properties. Nat Med (2009) 1.31

Thymus-autonomous T cell development in the absence of progenitor import. J Exp Med (2012) 1.28

Memories that last forever: strategies for optimizing vaccine T-cell memory. Blood (2009) 1.23

Thymic recovery after allogeneic hematopoietic cell transplantation with non-myeloablative conditioning is limited to patients younger than 60 years of age. Haematologica (2010) 1.19

IL-7 gene therapy in aging restores early thymopoiesis without reversing involution. J Immunol (2004) 1.16

Thymocytes may persist and differentiate without any input from bone marrow progenitors. J Exp Med (2012) 1.12

Il-7 and not stem cell factor reverses both the increase in apoptosis and the decline in thymopoiesis seen in aged mice. J Immunol (2001) 1.08

Elevated interleukin-7 levels not sufficient to maintain T-cell homeostasis during simian immunodeficiency virus-induced disease progression. Blood (2003) 1.06

Short-term inhibition of p53 combined with keratinocyte growth factor improves thymic epithelial cell recovery and enhances T-cell reconstitution after murine bone marrow transplantation. Blood (2009) 0.98

Flagellin, a TLR5 agonist, reduces graft-versus-host disease in allogeneic hematopoietic stem cell transplantation recipients while enhancing antiviral immunity. J Immunol (2011) 0.93

An engineered GM-CSF-CCL2 fusokine is a potent inhibitor of CCR2-driven inflammation as demonstrated in a murine model of inflammatory arthritis. J Immunol (2009) 0.93

GMCSF-interleukin fusion cytokines induce novel immune effectors that can serve as biopharmaceuticals for treatment of autoimmunity and cancer. J Intern Med (2011) 0.92

A GMCSF and IL-15 fusokine leads to paradoxical immunosuppression in vivo via asymmetrical JAK/STAT signaling through the IL-15 receptor complex. Blood (2006) 0.91

A fusion of GMCSF and IL-21 initiates hypersignaling through the IL-21Ralpha chain with immune activating and tumoricidal effects in vivo. Mol Ther (2010) 0.90

Engineered fusokine GIFT4 licenses the ability of B cells to trigger a tumoricidal T-cell response. Cancer Res (2014) 0.90

Inhibition of STAT3 expression by siRNA suppresses growth and induces apoptosis in laryngeal cancer cells. Acta Pharmacol Sin (2005) 0.90

A dendritic cell population generated by a fusion of GM-CSF and IL-21 induces tumor-antigen-specific immunity. J Immunol (2010) 0.86

Memory CD44(int) CD8 T cells show increased proliferative responses and IFN-gamma production following antigenic challenge in vitro. Int Immunol (1999) 0.85

A fusion cytokine coupling GMCSF to IL9 induces heterologous receptor clustering and STAT1 hyperactivation through JAK2 promiscuity. PLoS One (2013) 0.81

Enhancement of cytotoxic T-lymphocyte response in aged mice by a novel treatment with recombinant AdIL-12 and wild-type adenovirus in rapid succession. Mol Ther (2008) 0.80

Concise review: engineering the fusion of cytokines for the modulation of immune cellular responses in cancer and autoimmune disorders. Stem Cells Transl Med (2014) 0.79

GIFT15 fusokine to foil immunity's follies. Immunotherapy (2009) 0.78